🔗 Share this article

As the US undertakes sweeping adjustments to its immunization schedules, an unexpected name has surfaced in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccines during the global health crisis and has concentrated on potential deaths following COVID-19 vaccination in her recent time at the FDA.

Planned Changes to Childhood Immunization Program

Health officials had intended to unveil radical revisions to the childhood vaccination calendar in December, bringing the US with Denmark’s national calendar, it is understood – a major change that would place the US out of step with many the world with little proof for improved outcomes. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to lead the office this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for halting some childhood shot schedules in the US so as to align more in line with Denmark, a country with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

The appointee has little discernible experience in medication creation, regulation or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in leading a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of the center would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who headed the center have had.”

This division has an immense workload at the agency, the former commissioner emphasized.

“Many people just pays attention on the new drug program, but the generic drug division approves numerous generic medications. There’s a biosimilars program, over-the-counter program and more, and each of these must be looked after,” Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a significant management aspect to the position, which manages over 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” she said.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a representative said that the “questions are based on incorrect presumptions”.

“Her experience aligns with the functions of her position,” the spokesperson stated, pointing to the time Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg inherits the agency head's new fast-track approval initiative, a disputed rapid drug-approval program that apparently concerned her former heads. “By what process are these therapies being selected for this voucher program? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he stated, “the agency looks to be trending towards less stringent regulations of all drugs, aside from shots.”

Public History on Immunizations

Regarding immunizations, Høeg has a more established, if problematic, track record, some experts said. She authored a study using unverified volunteer-provided data to determine the incidence of heart inflammation following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Included in her “wish list” for the new federal leadership included revising guidelines for new vaccines and halting “non-essential” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly proposed excluding young men from receiving COVID-19 vaccinations.

“She is an complete dogmatist who commences with her conclusions and reverse-engineers to fit the science in a very misleading, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|